Opening book details…
Can I read Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma on EtoBox?
Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma by Michael B. Livingston; Megan H. Jagosky; Myra M. Robinson; William A. Ahrens; Jennifer H. Benbow; Carol J. Farhangfar; David M. Foureau; Deirdre M. Maxwell; Emily A. Baldrige; Xhevahire Begic; James T. Symanowski; Nury M. Steuerwald; Colin J. Anderson; Joshua C. Patt; Jeffrey S. Kneisl; Edward S. Kim is a Medicine article available to read on EtoBox.
What is Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma about?
Abstract Purpose: Doxorubicin is standard therapy for advanced soft-tissue sarcoma (STS) with minimal improvement in efficacy and increased toxicity with addition of other cytotoxic agents. Pembrolizumab monotherapy has demonstrated modest activity and tolerability in previous advanced STS studies. This study combined pembrolizumab with doxorubicin to assess safety and efficacy in frontline and relapsed settings of advanced STS. Patients and Methods: This single-center, single-arm, phase II trial enrolled patients with unresectable or metastatic STS with no prior anthracycline therapy. Patients received pembrolizumab 200 mg i.v. and doxorubicin (60 mg/m2 cycle 1 with subsequent escalation to 75 mg/m2 as tolerated). The primary endpoint was safety. Secondary endpoints included overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) based on RECIST v1.1 guidelines. Results: Thirty patients were enrolled (53.3% female; median age 61.5 years; 87% previously untreated) with 4 (13.3%) patients continuing treatment. The study met its primary safety endpoint by prespecified Bayesian stopping rules. The majority of grade 3+ treatment-emergent adverse events
Who reads Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Michael B. Livingston; Megan H. Jagosky; Myra M. Robinson; William A. Ahrens; Jennifer H. Benbow; Carol J. Farhangfar; David M. Foureau; Deirdre M. Maxwell; Emily A. Baldrige; Xhevahire Begic; James T. Symanowski; Nury M. Steuerwald; Colin J. Anderson; Joshua C. Patt; Jeffrey S. Kneisl; Edward S. Kim
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)